Skip header and navigation

Refine By

155733 records – page 1 of 15574.

A < 1.7 cM interval is responsible for Dmo1 obesity phenotypes in OLETF rats.

https://arctichealth.org/en/permalink/ahliterature47295
Source
Clin Exp Pharmacol Physiol. 2004 Jan-Feb;31(1-2):110-2
Publication Type
Article
Author
Takeshi K Watanabe
Shiro Okuno
Yuki Yamasaki
Toshihide Ono
Keiko Oga
Ayako Mizoguchi-Miyakita
Hideo Miyao
Mikio Suzuki
Hiroshi Momota
Yoshihiro Goto
Hiroichi Shinomiya
Haretsugu Hishigaki
Isamu Hayashi
Toshihiro Asai
Shigeyuki Wakitani
Toshihisa Takagi
Yusuke Nakamura
Akira Tanigami
Author Affiliation
Otsuka GEN Research Institute, Otsuka Pharmaceutical Co. Ltd., 463-10 Kagasuno, Kawauchi-cho, Tokushima 771-0192, Japan. tkw_watanabe@research.otsuka.co.jp
Source
Clin Exp Pharmacol Physiol. 2004 Jan-Feb;31(1-2):110-2
Language
English
Publication Type
Article
Keywords
Animals
Animals, Congenic
Body Weight - genetics
Crosses, Genetic
Diabetes Mellitus - genetics
Female
Hyperglycemia - genetics
Hyperlipidemia - blood - genetics
Male
Obesity
Phenotype
Rats
Rats, Inbred BN
Rats, Inbred OLETF
Research Support, Non-U.S. Gov't
Abstract
1. Dmo1 (Diabetes Mellitus OLETF type I) is a major quantitative trait locus for dyslipidaemia, obesity and diabetes phenotypes of male Otsuka Long Evans Tokushima Fatty (OLETF) rats. 2. Our congenic lines, produced by transferring Dmo1 chromosomal segments from the non-diabetic Brown Norway (BN) rat into the OLETF strain, have confirmed the strong, wide-range therapeutic effects of Dmo1 on dyslipidaemia, obesity and diabetes in the fourth (BC4) and fifth (BC5) generations of congenic animals. Analysis of a relatively small number of BC5 rats (n = 71) suggested that the critical Dmo1 interval lies within a
PubMed ID
14756694 View in PubMed
Less detail

The 1 alpha-hydroxylase locus is not linked to calcium stone formation or calciuric phenotypes in French-Canadian families.

https://arctichealth.org/en/permalink/ahliterature206213
Source
J Am Soc Nephrol. 1998 Mar;9(3):425-32
Publication Type
Article
Date
Mar-1998
Author
P. Scott
D. Ouimet
Y. Proulx
M L Trouvé
G. Guay
B. Gagnon
L. Valiquette
A. Bonnardeaux
Author Affiliation
Service de Néphrologie, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.
Source
J Am Soc Nephrol. 1998 Mar;9(3):425-32
Date
Mar-1998
Language
English
Publication Type
Article
Keywords
25-Hydroxyvitamin D3 1-alpha-Hydroxylase - genetics - metabolism
Adult
Calcium - urine
Canada
European Continental Ancestry Group - genetics
Family Health
Female
France - ethnology
Genetic Linkage
Genetic Markers - genetics
Humans
Kidney Calculi - enzymology - genetics
Male
Middle Aged
Nuclear Family
Pedigree
Phenotype
Vitamin D - blood
Abstract
Calcium urolithiasis is often associated with increased intestinal absorption and urine excretion of calcium, and has been suggested to result from increased vitamin D production. The role of the enzyme 1 alpha-hydroxylase, the rate-limiting step in active vitamin D production, was evaluated in 36 families, including 28 sibships with at least a pair of affected sibs, using qualitative and quantitative trait linkage analyses. Sibs with a verified calcium urolithiasis passage (n = 117) had higher 24-h calciuria (P = 0.03), oxaluria (P = 0.02), fasting and postcalcium loading urine calcium/creatinine (Ca/cr) ratios (P = 0.008 and P = 0.002, respectively), and serum 1,25(OH)2 vitamin D levels (P = 0.02) compared with nonstone-forming sibs (n = 120). Markers from a 9-centiMorgan interval encompassing the VDD1 locus on chromosome 12q13-14 (putative 1 alpha-hydroxylase) were analyzed in 28 sibships (146 sib pairs) of single and recurrent stone formers and in 14 sibships (65 sib pairs) with recurrent-only (> or = 3 episodes) stone-forming sibs. Two-point and multipoint analyses did not reveal excess in alleles shared among affected sibs at the VDD1 locus. Linkage of stone formation to the VDD1 locus could be excluded, respectively, with a lambda d of 2.0 (single and recurrent stone formers) and 3.25 (recurrent stone formers). Quantitative trait analyses revealed no evidence for linkage to 24-h calciuria and oxaluria, serum 1,25(OH)2 vitamin D levels, and Ca/cr ratios. This study shows absence of linkage of the putative 1 alpha-hydroxylase locus to calcium stone formation or to quantitative traits associated with idiopathic hypercalciuria. In addition, there is coaggregation of calciuric and oxaluric phenotypes with stone formation.
PubMed ID
9513904 View in PubMed
Less detail

1 Canadian Field Hospital in Haiti: surgical experience in earthquake relief.

https://arctichealth.org/en/permalink/ahliterature122035
Source
Can J Surg. 2012 Aug;55(4):271-4
Publication Type
Article
Date
Aug-2012
Author
Max Talbot
Bethann Meunier
Vincent Trottier
Michael Christian
Tracey Hillier
Chris Berger
Vivian McAlister
Scott Taylor
Author Affiliation
1 Canadian Field Hospital, Canadian Forces, Montreal, QC. max_talbot@hotmail.com
Source
Can J Surg. 2012 Aug;55(4):271-4
Date
Aug-2012
Language
English
Publication Type
Article
Keywords
Canada
Disaster Planning - organization & administration
Earthquakes
Female
Haiti
Hospitals, Packaged - organization & administration
Humans
International Cooperation
Male
Multiple Trauma - etiology - surgery
Operating Rooms
Relief Work - organization & administration
Surgical Procedures, Operative - statistics & numerical data
Abstract
The Canadian Forces' (CF) deployable hospital, 1 Canadian Field Hospital, was deployed to Haiti after an earthquake that caused massive devastation. Two surgical teams performed 167 operations over a 39-day period starting 17 days after the index event. Most operations were unrelated to the earthquake. Replacing or supplementing the destroyed local surgical capacity for a brief period after a disaster can be a valuable contribution to relief efforts. For future humanitarian operations/disaster response missions, the CF will study the feasibility of accelerating the deployment of surgical capabilities.
Notes
Cites: Disasters. 2000 Sep;24(3):262-7011026159
Cites: Prehosp Disaster Med. 2003 Oct-Dec;18(4):278-9015310039
Cites: Disaster Manag Response. 2005 Jan-Mar;3(1):11-615627125
Cites: Mil Med. 2007 May;172(5):471-717521092
Cites: Prehosp Disaster Med. 2008 Mar-Apr;23(2):144-51; discussion 152-318557294
Cites: Ann Intern Med. 2010 Jun 1;152(11):733-720197507
Cites: Prehosp Disaster Med. 2009 Jan-Feb;24(1):9-1019557952
Cites: Science. 2010 Feb 5;327(5966):638-920133550
Cites: Nature. 2010 Feb 18;463(7283):878-920164905
Cites: N Engl J Med. 2010 Mar 18;362(11):e3820200362
Cites: Prehosp Disaster Med. 2009 Jan-Feb;24(1):3-819557951
PubMed ID
22854149 View in PubMed
Less detail

1. Fatal acute hepatitis in infectious mononucleosis in a forensic setting: a case report.

https://arctichealth.org/en/permalink/ahliterature173239
Source
Med Sci Law. 2005 Jul;45(3):261-4
Publication Type
Article
Date
Jul-2005
Author
Anny Sauvageau
Stéphanie Racette
Author Affiliation
Laboratoire de Sciences Judiciaires et de Médecine Légale, Edifice Wilfrid-Derome 1701, Parthenais Street, 12th floor, Montreal, Quebec, Canada H2K 3S7. a.sauvageau@msp.gouv.qc.ca
Source
Med Sci Law. 2005 Jul;45(3):261-4
Date
Jul-2005
Language
English
Publication Type
Article
Keywords
Acute Disease
Adolescent
Fatal Outcome
Female
Forensic Medicine
Hepatitis - complications - physiopathology
Humans
Infectious Mononucleosis - complications
Quebec
Abstract
Mononucleosis is generally considered a benign, self-limited disease. However, though uncommon, fatal complications are sometimes encountered. Deaths from liver failure, splenic rupture, respiratory obstruction, neurological complications, secondary infections and bleeding complications have been described. In the forensic setting, there are a few reports of sudden and unexplained deaths from splenic rupture and upper airway obstruction. We report here the first case of sudden and unexplained death from acute hepatitis in infectious mononucleosis presenting as a suspicious death.
PubMed ID
16117288 View in PubMed
Less detail

1H-MRS Measured Ectopic Fat in Liver and Muscle in Danish Lean and Obese Children and Adolescents.

https://arctichealth.org/en/permalink/ahliterature273208
Source
PLoS One. 2015;10(8):e0135018
Publication Type
Article
Date
2015
Author
Cilius Esmann Fonvig
Elizaveta Chabanova
Ehm Astrid Andersson
Johanne Dam Ohrt
Oluf Pedersen
Torben Hansen
Henrik S Thomsen
Jens-Christian Holm
Source
PLoS One. 2015;10(8):e0135018
Date
2015
Language
English
Publication Type
Article
Keywords
Adolescent
Anthropometry
Blood Glucose - analysis
Blood pressure
Body mass index
Body Weight
Cardiovascular Diseases - physiopathology
Child
Cross-Sectional Studies
Denmark
Dyslipidemias - blood
Fatty Liver - pathology
Female
Humans
Insulin - blood
Insulin Resistance
Intra-Abdominal Fat - pathology
Linear Models
Lipids - blood
Liver - metabolism - pathology
Male
Muscles - pathology
Overweight
Pediatric Obesity - blood - pathology
Proton Magnetic Resonance Spectroscopy
Puberty
Sex Factors
Subcutaneous Fat - pathology
Abstract
This cross sectional study aims to investigate the associations between ectopic lipid accumulation in liver and skeletal muscle and biochemical measures, estimates of insulin resistance, anthropometry, and blood pressure in lean and overweight/obese children.
Fasting plasma glucose, serum lipids, serum insulin, and expressions of insulin resistance, anthropometry, blood pressure, and magnetic resonance spectroscopy of liver and muscle fat were obtained in 327 Danish children and adolescents aged 8-18 years.
In 287 overweight/obese children, the prevalences of hepatic and muscular steatosis were 31% and 68%, respectively, whereas the prevalences in 40 lean children were 3% and 10%, respectively. A multiple regression analysis adjusted for age, sex, body mass index z-score (BMI SDS), and pubertal development showed that the OR of exhibiting dyslipidemia was 4.2 (95%CI: [1.8; 10.2], p = 0.0009) when hepatic steatosis was present. Comparing the simultaneous presence of hepatic and muscular steatosis with no presence of steatosis, the OR of exhibiting dyslipidemia was 5.8 (95%CI: [2.0; 18.6], p = 0.002). No significant associations between muscle fat and dyslipidemia, impaired fasting glucose, or blood pressure were observed. Liver and muscle fat, adjusted for age, sex, BMI SDS, and pubertal development, associated to BMI SDS and glycosylated hemoglobin, while only liver fat associated to visceral and subcutaneous adipose tissue and intramyocellular lipid associated inversely to high density lipoprotein cholesterol.
Hepatic steatosis is associated with dyslipidemia and liver and muscle fat depositions are linked to obesity-related metabolic dysfunctions, especially glycosylated hemoglobin, in children and adolescents, which suggest an increased cardiovascular disease risk.
Notes
Cites: Child Obes. 2012 Dec;8(6):533-4123181919
Cites: Int J Pediatr Obes. 2011 Aug;6(3-4):188-9621529264
Cites: Int J Obes (Lond). 2014 Jan;38(1):40-523828099
Cites: Pediatr Diabetes. 2014 May;15(3):151-6124754463
Cites: Semin Liver Dis. 2001;21(1):3-1611296695
Cites: Pediatr Clin North Am. 2011 Dec;58(6):1375-92, x22093857
Cites: Obesity (Silver Spring). 2012 Feb;20(2):371-521869763
Cites: AJR Am J Roentgenol. 2012 Jul;199(1):2-722733887
Cites: J Clin Endocrinol Metab. 2012 Jul;97(7):E1099-10522508709
Cites: Nutr Metab Cardiovasc Dis. 2009 Feb;19(2):146-5219171470
Cites: Pediatr Diabetes. 2014 Sep;15 Suppl 20:4-1725182305
Cites: Int J Obes Relat Metab Disord. 2001 Feb;25(2):177-8411410817
Cites: J Clin Endocrinol Metab. 2001 Dec;86(12):5755-6111739435
Cites: Diabetes. 2002 Apr;51(4):1022-711916921
Cites: Circulation. 2003 Mar 25;107(11):1562-612654618
Cites: Lancet. 2003 Sep 20;362(9388):951-714511928
Cites: Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-7615286277
Cites: Int J Obes Relat Metab Disord. 2004 Oct;28(10):1257-6315278103
Cites: Nutr Rev. 1981 Feb;39(2):43-557010232
Cites: Stat Med. 1992 Jul;11(10):1305-191518992
Cites: Am J Clin Nutr. 1993 Oct;58(4):463-78379501
Cites: Diabetes. 1997 Jun;46(6):983-89166669
Cites: Diabetologia. 1999 Jan;42(1):113-610027589
Cites: Diabetes. 1999 Oct;48(10):2039-4410512371
Cites: Obesity (Silver Spring). 2006 Mar;14(3):357-6716648604
Cites: Pediatrics. 2006 Oct;118(4):1388-9317015527
Cites: Diabetes Care. 2007 Jan;30(1):89-9417192339
Cites: Eur J Clin Nutr. 2007 Jul;61(7):877-8317151586
Cites: Circulation. 2008 Jul 15;118(3):277-8318591439
Cites: Diabetes Care. 2009 Feb;32(2):342-718957533
Cites: J Clin Endocrinol Metab. 2009 Sep;94(9):3440-719531593
Cites: Am J Epidemiol. 2010 Jun 1;171(11):1195-20220457571
Cites: Eur J Endocrinol. 2010 Sep;163(3):413-920584996
Cites: J Clin Endocrinol Metab. 2010 Dec;95(12):5189-9820829185
Cites: J Clin Res Pediatr Endocrinol. 2010;2(3):100-621274322
Cites: Diabetologia. 2011 Apr;54(4):869-7521181394
Cites: Abdom Imaging. 2013 Apr;38(2):315-922736224
PubMed ID
26252778 View in PubMed
Less detail

1H MRS studies in the Finnish boron neutron capture therapy project: detection of 10B-carrier, L-p-boronophenylalanine-fructose.

https://arctichealth.org/en/permalink/ahliterature172386
Source
Eur J Radiol. 2005 Nov;56(2):154-9
Publication Type
Article
Date
Nov-2005
Author
M. Timonen
L. Kankaanranta
N. Lundbom
J. Collan
A. Kangasmäki
M. Kortesniemi
A-M Häkkinen
A. Lönngren
S. Karjalainen
M. Rasilainen
J. Leinonen
T. Huitti
J. Jääskeläinen
M. Kouri
S. Savolainen
S. Heikkinen
Author Affiliation
Department of Physical Sciences, University of Helsinki, POB 64, FIN-00014, Helsinki, Finland.
Source
Eur J Radiol. 2005 Nov;56(2):154-9
Date
Nov-2005
Language
English
Publication Type
Article
Keywords
Adult
Aged
Boron - therapeutic use
Boron Compounds - analysis - blood
Boron Neutron Capture Therapy
Brain Neoplasms - pathology - radiotherapy
Carcinoma - pathology - radiotherapy
Female
Finland
Fructose - analogs & derivatives - analysis - blood
Glioblastoma - pathology - radiotherapy
Humans
Hydrogen
Isotopes - therapeutic use
Magnetic Resonance Spectroscopy - methods
Male
Neoplasm Recurrence, Local - pathology - radiotherapy
Paranasal Sinus Neoplasms - pathology - radiotherapy
Phantoms, Imaging
Plasma
Radiopharmaceuticals - therapeutic use
Abstract
This article summarizes the current status of 1H MRS in detecting and quantifying a boron neutron capture therapy (BNCT) boron carrier, L-p-boronophenylalanine-fructose (BPA-F) in vivo in the Finnish BNCT project. The applicability of 1H MRS to detect BPA-F is evaluated and discussed in a typical situation with a blood containing resection cavity within the gross tumour volume (GTV). 1H MRS is not an ideal method to study BPA concentration in GTV with blood in recent resection cavity. For an optimal identification of BPA signals in the in vivo 1H MR spectrum, both pre- and post-infusion 1H MRS should be performed. The post-infusion spectroscopy studies should be scheduled either prior to or, less optimally, immediately after the BNCT. The pre-BNCT MRS is necessary in order to utilise the MRS results in the actual dose planning.
PubMed ID
16233888 View in PubMed
Less detail

1H NMR studies on human plasma lipids from newborn infants, healthy adults, and adults with tumors.

https://arctichealth.org/en/permalink/ahliterature25704
Source
Magn Reson Med. 1989 Jan;9(1):35-8
Publication Type
Article
Date
Jan-1989
Author
S. Eskelinen
Y. Hiltunen
J. Jokisaari
S. Virtanen
K. Kiviniitty
Author Affiliation
Department of Biomedical Physics, University of Oulu, Finland.
Source
Magn Reson Med. 1989 Jan;9(1):35-8
Date
Jan-1989
Language
English
Publication Type
Article
Keywords
Adult
Female
Humans
Hydrogen
Infant, Newborn - blood
Lactates - blood
Lipoproteins - blood
Magnetic Resonance Spectroscopy - diagnostic use
Male
Methane - blood
Neoplasms - blood
Protons
Abstract
The 1H NMR spectra of the lipid region of human plasma from healthy adults, neonates, and patients with malignant and nonmalignant tumors have been recorded on a JNM-GX400 FT spectrometer operating at 399.6 MHz for protons. The chemical shifts of methylene and methyl groups of plasma lipids were measured with respect to the higher field component of the methyl proton resonance of the lactate molecule. The results show that there are changes in the chemical shifts of the methylene proton resonances among the plasma from healthy adults, adults with tumors, and neonates. The shifts observed in the case of cancer patients and neonates are in the direction opposite to the shift measured from the plasma of healthy adults. Thus, the observed changes cannot be explained by the activity in the cell proliferation of tissues which is high in the cases of both healthy neonates and patients with malignant tumors, but they most probably reflect the different lipoprotein compositions of neonates, healthy adults, and adults with tumors.
PubMed ID
2540395 View in PubMed
Less detail

The 1-month prevalence of generalized anxiety disorder according to DSM-IV, DSM-V, and ICD-10 among nondemented 75-year-olds in Gothenburg, Sweden.

https://arctichealth.org/en/permalink/ahliterature124775
Source
Am J Geriatr Psychiatry. 2012 Nov;20(11):963-72
Publication Type
Article
Date
Nov-2012
Author
Nilsson, J
Östling, S
Waern, M
Karlsson, B
SigstrÖm, R
Xinxin Guo
Ingmar Skoog
Author Affiliation
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Source
Am J Geriatr Psychiatry. 2012 Nov;20(11):963-72
Date
Nov-2012
Language
English
Publication Type
Article
Keywords
Aged
Alzheimer Disease - diagnosis - epidemiology - psychology
Anxiety Disorders - diagnosis - epidemiology - psychology
Chronic Disease - epidemiology - psychology
Comorbidity
Cross-Sectional Studies
Depressive Disorder, Major - diagnosis - epidemiology - psychology
Diagnostic and Statistical Manual of Mental Disorders
Female
Geriatric Assessment - statistics & numerical data
Health Behavior
Health Surveys
Humans
International Classification of Diseases
Interview, Psychological
Life Style
Male
Obsessive-Compulsive Disorder - diagnosis - epidemiology - psychology
Phobic Disorders - diagnosis - epidemiology - psychology
Sweden
Abstract
To examine the 1-month prevalence of generalized anxiety disorder (GAD) according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), Diagnostic and Statistical Manual of Mental, Fifth Edition (DSM-V), and International Classification of Diseases, Tenth Revision (ICD-10), and the overlap between these criteria, in a population sample of 75-year-olds. We also aimed to examine comorbidity between GAD and other psychiatric diagnoses, such as depression.
During 2005-2006, a comprehensive semistructured psychiatric interview was conducted by trained nurses in a representative population sample of 75-year-olds without dementia in Gothenburg, Sweden (N = 777; 299 men and 478 women). All psychiatric diagnoses were made according to DSM-IV. GAD was also diagnosed according to ICD-10 and DSM-V.
The 1-month prevalence of GAD was 4.1% (N = 32) according to DSM-IV, 4.5% (N = 35) according to DSM-V, and 3.7% (N = 29) according to ICD-10. Only 46.9% of those with DSM-IV GAD fulfilled ICD-10 criteria, and only 51.7% and 44.8% of those with ICD-10 GAD fulfilled DSM-IV/V criteria. Instead, 84.4% and 74.3% of those with DSM-IV/V GAD and 89.7% of those with ICD-10 GAD had depression. Also other psychiatric diagnoses were common in those with ICD-10 and DSM-IV GAD. Only a small minority with GAD, irrespective of criteria, had no other comorbid psychiatric disorder. ICD-10 GAD was related to an increased mortality rate.
While GAD was common in 75-year-olds, DSM-IV/V and ICD-10 captured different individuals. Current definitions of GAD may comprise two different expressions of the disease. There was greater congruence between GAD in either classification system and depression than between DSM-IV/V GAD and ICD-10 GAD, emphasizing the close link between these entities.
PubMed ID
22549369 View in PubMed
Less detail

The 1% of the population accountable for 63% of all violent crime convictions.

https://arctichealth.org/en/permalink/ahliterature259131
Source
Soc Psychiatry Psychiatr Epidemiol. 2014 Apr;49(4):559-71
Publication Type
Article
Date
Apr-2014
Author
Falk, O
Wallinius, M
Lundström, S
Frisell, T
Anckarsäter, H
Kerekes, N
Source
Soc Psychiatry Psychiatr Epidemiol. 2014 Apr;49(4):559-71
Date
Apr-2014
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aggression - psychology
Criminals - psychology - statistics & numerical data
Female
Humans
Male
Mental Disorders - epidemiology - psychology
Middle Aged
Registries
Risk factors
Substance-Related Disorders - epidemiology
Sweden
Violence - psychology - statistics & numerical data
Abstract
Population-based studies on violent crime and background factors may provide an understanding of the relationships between susceptibility factors and crime. We aimed to determine the distribution of violent crime convictions in the Swedish population 1973-2004 and to identify criminal, academic, parental, and psychiatric risk factors for persistence in violent crime.
The nationwide multi-generation register was used with many other linked nationwide registers to select participants. All individuals born in 1958-1980 (2,393,765 individuals) were included. Persistent violent offenders (those with a lifetime history of three or more violent crime convictions) were compared with individuals having one or two such convictions, and to matched non-offenders. Independent variables were gender, age of first conviction for a violent crime, nonviolent crime convictions, and diagnoses for major mental disorders, personality disorders, and substance use disorders.
A total of 93,642 individuals (3.9%) had at least one violent conviction. The distribution of convictions was highly skewed; 24,342 persistent violent offenders (1.0% of the total population) accounted for 63.2% of all convictions. Persistence in violence was associated with male sex (OR 2.5), personality disorder (OR 2.3), violent crime conviction before age 19 (OR 2.0), drug-related offenses (OR 1.9), nonviolent criminality (OR 1.9), substance use disorder (OR 1.9), and major mental disorder (OR 1.3).
The majority of violent crimes are perpetrated by a small number of persistent violent offenders, typically males, characterized by early onset of violent criminality, substance abuse, personality disorders, and nonviolent criminality.
Notes
Cites: JAMA Psychiatry. 2013 May;70(5):465-7123467760
Cites: Behav Genet. 2012 Jan;42(1):3-1821761238
Cites: Arch Gen Psychiatry. 2000 Oct;57(10):979-8611015816
Cites: Dev Psychopathol. 2001 Spring;13(2):355-7511393651
Cites: J Consult Clin Psychol. 1989 Dec;57(6):710-82600241
Cites: Arch Gen Psychiatry. 1992 Jun;49(6):476-831599373
Cites: Lancet. 1997 May 24;349(9064):1498-5049167458
Cites: Am J Psychiatry. 1997 Jun;154(6):840-59167513
Cites: Psychol Bull. 1998 Mar;123(2):123-429522681
Cites: Arch Gen Psychiatry. 1998 May;55(5):393-4019596041
Cites: Psychiatry Clin Neurosci. 2005 Feb;59(1):25-915679536
Cites: Sex Abuse. 2005 Jul;17(3):269-9216121839
Cites: Eur J Public Health. 2006 Jun;16(3):260-6616446293
Cites: Am J Psychiatry. 2006 Aug;163(8):1397-40316877653
Cites: Am J Epidemiol. 2006 Dec 15;164(12):1199-20817032695
Cites: Soc Psychiatry Psychiatr Epidemiol. 2007 Jun;42(6):477-8417450452
Cites: J Clin Psychiatry. 2008 Jan;69(1):12-2218312033
Cites: J Abnorm Psychol. 2008 May;117(2):396-40518489215
Cites: Int J Law Psychiatry. 2008 Aug-Sep;31(4):374-8318678408
Cites: BMC Psychiatry. 2008;8:9219032787
Cites: J Clin Psychiatry. 2009 Mar;70(3):362-919284931
Cites: PLoS Med. 2009 Aug;6(8):e100012019668362
Cites: Nord J Psychiatry. 2009;63(4):292-30019229735
Cites: Schizophr Bull. 2010 Jul;36(4):702-1218990713
Cites: Arch Sex Behav. 2010 Oct;39(5):1161-919888644
Cites: Psychol Med. 2011 Jan;41(1):97-10520334717
Cites: Arch Gen Psychiatry. 2010 Dec;67(12):1325-621135334
Cites: Clin Psychol Rev. 2011 Jul;31(5):872-8221550331
Cites: PLoS One. 2011;6(10):e2576822022445
Cites: Arch Gen Psychiatry. 2000 May;57(5):494-50010807490
PubMed ID
24173408 View in PubMed
Less detail

A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.

https://arctichealth.org/en/permalink/ahliterature206818
Source
Chest. 1998 Jan;113(1):131-41
Publication Type
Article
Date
Jan-1998
Author
R. Grossman
J. Mukherjee
D. Vaughan
C. Eastwood
R. Cook
J. LaForge
N. Lampron
Author Affiliation
Department of Respiratory Medicine, Mount Sinai Hospital, Toronto, ON.
Source
Chest. 1998 Jan;113(1):131-41
Date
Jan-1998
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Anti-Infective Agents - adverse effects - economics - therapeutic use
Bronchitis - drug therapy - economics
Canada
Chronic Disease
Ciprofloxacin - adverse effects - economics - therapeutic use
Cost-Benefit Analysis
Female
Follow-Up Studies
Health Care Costs
Hospitalization - economics
Humans
Male
Middle Aged
Predictive value of tests
Quality-Adjusted Life Years
Recurrence
Treatment Outcome
Abstract
To evaluate the costs, consequences, effectiveness, and safety of ciprofloxacin vs standard antibiotic care in patients with an initial acute exacerbation of chronic bronchitis (AECB) as well as recurrent AECBs over a 1-year period.
Randomized, multicenter, parallel-group, open-label study.
Outpatient general practice.
A total of 240 patients, 18 years or older with chronic bronchitis, with a history of frequent exacerbations (three or more in the past year) presenting with a type 1 or 2 AECB (two or more of increased dyspnea, increased sputum volume, or sputum purulence).
The assessment included AECB symptoms, antibiotics prescribed, concomitant medications, adverse events, hospitalizations, emergency department visits, outpatient resources such as diagnostic tests, procedures, and patient and caregiver out-of-pocket expenses. Patients completed the Nottingham Health Profile, St. George's Respiratory Questionnaire, and the Health Utilities Index. The parameters were recorded with each AECB and at regular quarterly intervals for 1 year. These variables were compared between the ciprofloxacin-treated group and the usual-care-treated group.
Patients receiving ciprofloxacin experienced a median of two AECBs per patient compared to a median of three AECBs per patient receiving usual care. The mean annualized total number of AECB-symptom days was 42.9+/-2.8 in the ciprofloxacin arm compared to 45.6+/-3.0 days in the usual-care arm (p=0.50). The overall duration of the average AECB was 15.2+/-0.6 days for the ciprofloxacin arm compared to 16.3+/-0.6 days for the usual-care arm. Treatment with ciprofloxacin tended to accelerate the resolution of all AECBs compared to usual care (relative risk=1.20; 95% confidence interval [CI], 0.91 to 1.58; p=0.19). Treatment assignment did not affect the interexacerbation period but a history of severe bronchitis, prolonged chronic bronchitis, and an increased number of AECBs in the past year were associated with shorter exacerbations-free periods. There was a slight, but not statistically significant, improvement in all quality of life measures with ciprofloxacin over usual care. The only factors predictive of hospitalization were duration of chronic bronchitis (odds ratio=4.6; 95% CI, 1.6, 13.0) and severity of chronic bronchitis (odds ratio=4.3; 95% CI, 0.8, 24.6). The incremental cost difference of $578 Canadian in favor of usual care was not significant (95% CI, -$778, $1,932). The cost for the ciprofloxacin arm over the usual care arm was $18,588 Canadian per quality-adjusted life year gained. When the simple base case analysis was expanded to examine the effect of risk stratification, the presence of moderate or severe bronchitis and at least four AECBs in the previous year changed the economic and clinical analysis to one favorable to ciprofloxacin with the ciprofloxacin-treated group having a better clinical outcome at lower cost ("win-win" scenario).
Treatment with ciprofloxacin tended to accelerate the resolution of all AECBs compared to usual care; however, the difference was not statistically significant. Further, usual care was found to be more reflective of best available care rather than usual first-line agents such as amoxicillin, tetracycline, or trimethoprim-sulfamethoxazole as originally expected. Despite the similar antimicrobial activities and broad-spectrum coverage of both ciprofloxacin and usual care, the trends in clinical outcomes and all quality of life measurements favor ciprofloxacin. In patients suffering from an AECB with a history of moderate to severe chronic bronchitis and at least four AECBs in the previous year, ciprofloxacin treatment offered substantial clinical and economic benefits. In these patients, ciprofloxacin may be the preferred first antimicrobial choice.
PubMed ID
9440580 View in PubMed
Less detail

155733 records – page 1 of 15574.